Krankenhaus Nordwest GmbH

Krankenhaus Nordwest GmbH stands as a leading institution in gastrointestinal malignancies research, conducting extensive clinical trials across esophageal, gastric, biliary tract, pancreatic, and colorectal cancers. The center demonstrates particular expertise in perioperative treatment strategies, combining novel immunotherapy agents with conventional chemotherapy and radiation approaches.

• Advanced gastrointestinal oncology with focus on esophageal adenocarcinoma, gastric cancer, and gastroesophageal junction tumors, including organ-preservation strategies and neoadjuvant immunotherapy combinations
• Lung cancer therapeutics encompassing non-small cell lung cancer (NSCLC) with targeted mutations (KRAS G12C, EGFR, ALK) and small cell lung cancer, evaluating next-generation immunotherapy and antibody-drug conjugates
• Precision oncology in biliary tract cancer and cholangiocarcinoma with specific molecular alterations including FGFR2 fusions, HER2-positive tumors, and IDH1 mutations
• Colorectal cancer research spanning early-stage disease to metastatic settings, including circulating tumor DNA-guided adjuvant therapy, preoperative systemic therapy, and molecular subtype-directed treatments

The research center participates in groundbreaking studies combining targeted therapy with immunotherapy, including novel antibody-drug conjugates and KRAS inhibitors. Their comprehensive portfolio includes Phase I through Phase III trials evaluating innovative treatment combinations for pancreatic ductal adenocarcinoma, urothelial carcinoma, and rare malignancies. The center's involvement in platform trials and biomarker-driven studies demonstrates commitment to personalized medicine approaches, particularly in HER2-positive, MSI-high/dMMR, and molecularly defined tumor populations across multiple solid tumor types.